bortezomib 
takeda
['mmsm']
#asco22 #mmsm plenary session median f/u~6yrs asct vs.rvd:pfs better of 21 mo in all (more benefit in high risk)
it seems in us,if asct is not done upfront,only 1/4 pts will get it later
dara use is low at progression, heterogeneous ttt 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities. No COI